OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD): Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) (NCT04757610), a randomized phase 3 study. The primary outcome is Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) Letters.

2. Clinical Question

3. Trial Design

NCT04757610 is a phase 3, multicentre, randomized, parallel-group study of OPT-302 combined with ranibizumab compared with ranibizumab alone in participants with nAMD. The registry lists an enrollment of 986 and the status as terminated. The record gives a study start date of 2021-03-12 and a primary completion date of 2025-03-31. It describes the study as lasting 2 years, with primary efficacy determined at Week 52.

Three treatment groups are listed: standard-dosed OPT-302 with ranibizumab, extended-dosed OPT-302 with ranibizumab, and ranibizumab with sham. Ranibizumab was administered at 4-weekly intervals in each group. The extended OPT-302 schedule changed to 8-weekly intervals after three 4-weekly treatments; sham injections were used at visits when OPT-302 was not administered. The registry identifies the study as randomized, parallel-group, and sham-controlled. Its masking field says quadruple, while the brief summary describes the study as double-masked. The registry record does not explain this difference in masking descriptions.

The primary endpoint is a continuous measure: mean change in ETDRS BCVA letters from baseline to Week 52. The efficacy population is the modified Intent-to-Treat set, defined in the record as randomized participants who received at least one dose of study medication. The posted primary result includes a mean and standard error for each group and sponsor analyses using MMRM. Four secondary outcomes are also listed, covering visual-acuity gains, CNV area, and retinal fluid or cyst findings. The registry record does not report the reasons for termination or the original design assumptions for the study.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Participants who met all inclusion criteria and none of the exclusion criteria were enrolled in the study. 1 subject (in the 0.5 mg ranibizumab with standard dosing 2.0 mg OPT-302 arm) was enrolled, but never treated.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Modified Intent-to-Treat (mITT) analysis set - comprised all randomised participants with at least one dose of study medication. Participants were analysed according to the study medication to which they were randomised for all efficacy analyses.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Modified Intent-to-Treat (mITT) dataset comprised all randomised participants with at least one dose of study medication. Participants were analysed according to the study medication to which they were randomised for all efficacy analyses.

6. Primary Endpoint

The registry lists the primary outcome as Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) Letters, measured over Baseline to Week 52.

The primary endpoint is the mean change from baseline to Week 52 in ETDRS BCVA letter score in the study eye. ETDRS letters are a standardized way to record visual acuity; the endpoint therefore expresses change as letters read. A positive change represents improvement relative to baseline, while a negative change represents deterioration, as stated in the registry description.

Using a continuous outcome retains information about the amount of change across participants rather than reducing the result to a yes-or-no threshold. The group mean describes the average change, while the standard error indicates the estimated uncertainty around that mean. Comparing group means addresses whether average change differs between randomized treatment groups. The endpoint is clinically relevant to the study question because it focuses on visual acuity in nAMD, but a group average does not describe every participant’s experience.

The registry identifies the primary analysis as an MMRM in the overall population, with the endpoint assessed from baseline to Week 52. MMRM is a repeated-measures approach that can use outcome observations across study visits to estimate the specified comparison. The registry record does not report the detailed model specification, including its covariates or covariance structure. The endpoint result should therefore be read as the stated Week 52 mean change and the reported group contrast, with uncertainty considered alongside the point estimate.

7. Results Posted in the Registry

• 0.5 mg Ranibizumab With Extended Dosing 2.0 mg OPT-302: mean 12.41 versus 13.20 on control; difference -0.79 (95% CI -2.81 to 1.23), standardized effect d = -0.06; z-test p = 0.444.
• 0.5 mg Ranibizumab With Sham: mean 14.30 versus 13.20 on control; difference 1.10 (95% CI -0.91 to 3.11), standardized effect d = 0.08; z-test p = 0.282.

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Participants Gaining 15 or More ETDRS BCVA Letters

• Endpoint type: Binary: the number of participants with the event, compared as proportions.
• Test: Unadjusted two-proportion z-test, with a Wald 95% confidence interval for the risk difference.
• Result:
  • 0.5 mg Ranibizumab With Extended Dosing 2.0 mg OPT-302: 46.6% (135/290) versus 54.5% (159/292) on control; risk difference -7.9 percentage points (95% CI -16.0 to 0.2), risk ratio 0.85 (0.73–1.01); unadjusted two-proportion z-test p = 0.057.
  • 0.5 mg Ranibizumab With Sham: 55.2% (164/297) versus 54.5% (159/292) on control; risk difference 0.8 percentage points (95% CI -7.3 to 8.8), risk ratio 1.01 (0.88–1.17); unadjusted two-proportion z-test p = 0.852.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between 0.5 mg Ranibizumab With Extended Dosing 2.0 mg OPT-302 and the control. The interval gives the range of effects that remain compatible with the data.
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between 0.5 mg Ranibizumab With Sham and the control. The interval gives the range of effects that remain compatible with the data.

Participants Gaining 10 More ETDRS BCVA Letters

• Endpoint type: Binary: the number of participants with the event, compared as proportions.
• Test: Unadjusted two-proportion z-test, with a Wald 95% confidence interval for the risk difference.
• Result:
  • 0.5 mg Ranibizumab With Extended Dosing 2.0 mg OPT-302: 62.8% (182/290) versus 67.8% (198/292) on control; risk difference -5.0 percentage points (95% CI -12.8 to 2.7), risk ratio 0.93 (0.82–1.04); unadjusted two-proportion z-test p = 0.201.
  • 0.5 mg Ranibizumab With Sham: 68.0% (202/297) versus 67.8% (198/292) on control; risk difference 0.2 percentage points (95% CI -7.3 to 7.7), risk ratio 1.00 (0.90–1.12); unadjusted two-proportion z-test p = 0.957.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between 0.5 mg Ranibizumab With Extended Dosing 2.0 mg OPT-302 and the control. The interval gives the range of effects that remain compatible with the data.
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between 0.5 mg Ranibizumab With Sham and the control. The interval gives the range of effects that remain compatible with the data.

Change in Choroidal Neovascularisation (CNV) Area by Fluorescein Angiography (FA)

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard errors.
• Result:
  • 0.5 mg Ranibizumab With Extended Dosing 2.0 mg OPT-302: mean -3.90 versus -3.36 on control; difference -0.54 (95% CI -1.58 to 0.49), standardized effect d = -0.12; z-test p = 0.305.
  • 0.5 mg Ranibizumab With Sham: mean -3.24 versus -3.36 on control; difference 0.12 (95% CI -0.86 to 1.10), standardized effect d = 0.03; z-test p = 0.809.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between 0.5 mg Ranibizumab With Extended Dosing 2.0 mg OPT-302 and the control. The interval gives the range of effects that remain compatible with the data.
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between 0.5 mg Ranibizumab With Sham and the control. The interval gives the range of effects that remain compatible with the data.

Across the posted secondary outcomes, the pattern is mixed rather than a uniform separation favoring one group. The outcomes cover threshold-based visual-acuity gains, change in CNV area, and absence of specified retinal fluid findings. These measures address related but different aspects of disease and response, so they need not move together. The secondary results offer additional context for the primary Week 52 visual-acuity comparison, but do not replace it.

The posted secondary comparisons are largely simple, unadjusted contrasts. Their estimates and intervals should be read with attention to the outcome definitions, analysis denominators, and contrast direction. A point estimate alone is not enough to establish a reliable group difference; uncertainty intervals indicate whether the data are compatible with a range of effects. The registry does not provide sponsor-reported analyses for these secondary outcomes in the posted results included in this record.

Multiplicity matters because examining several outcomes and contrasts creates multiple opportunities for a seemingly notable result. Unless an analysis plan controls that process, individual unadjusted p-values do not account for the full set of tests and may overstate the strength of evidence. The registry record does not report a multiplicity adjustment or a hierarchy for interpreting secondary outcomes. Consequently, any isolated secondary finding should be considered exploratory and interpreted alongside the primary endpoint, not as independent confirmation of it.

In broad terms, the secondary outcomes do not supply a single consistent pattern that overrides the primary result. They may help describe the range of measured outcomes, but they cannot establish a definitive overall conclusion without the planned statistical framework, complete outcome information, and appropriate attention to multiplicity. Nor should differences in secondary endpoints be taken as proof of a change in the primary visual-acuity outcome.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Participants Gaining 15 or More ETDRS BCVA Letters
• Participants Gaining 10 More ETDRS BCVA Letters
• Change in Choroidal Neovascularisation (CNV) Area by Fluorescein Angiography (FA)
• Participants With Absence of Both Sub-retinal Fluid and Intra-retinal Cysts by SD-OCT

9. Statistical Interpretation

10. Statistical Methods Explained

Several statistical ideas help place the reported estimates in context. The endpoint is continuous, so the main summary is a group mean change in letters. A mean is an average, and it can make a group result easier to compare, but it does not show the full distribution of individual outcomes. The posted standard errors describe uncertainty in each estimated mean; they are not standard deviations and should not be read as the amount of variation among individual participants.

What does the MMRM analysis do?

The registry says the primary analysis used a mixed model for repeated measures, or MMRM, in the overall population. In general, repeated-measures models account for the fact that outcome measurements from the same participant across visits are related rather than independent. Such models can estimate group differences over time while using available repeated outcome observations under the model’s assumptions. The registry record does not report the detailed model specification, the visits included, the covariance structure, covariates, or the missing-data assumptions. Those details should not be inferred from the name of the method alone.

The sponsor’s reported primary comparisons are least-squares mean differences from MMRM, with 95% confidence intervals. Least-squares means are model-based estimates, rather than simply raw averages. Their contrasts can differ from an unadjusted comparison of posted group means because the model uses the specified repeated-measures structure and any model terms. The detailed terms are not reported in the registry record. The recalculated comparisons use posted means and standard errors, without that model adjustment, and are labelled as recalculated for that reason.

Why distinguish adjusted and unadjusted comparisons?

A statistical model can use information differently from a direct comparison of group summaries. It may account for repeated measurements or prespecified covariates, while a simple comparison does not. As a result, model estimates and unadjusted estimates need not match exactly. The sponsor analysis is the trial’s own reported analysis and takes precedence over a simple recalculation when describing the trial’s prespecified or official result. The registry record does not report a detailed statistical analysis plan with which to check all analysis choices.

The recalculated confidence intervals and p-values are useful as an independent, simple description of the posted summaries, but they should not be presented as if they were the sponsor’s MMRM output. A p-value measures how incompatible the observed data are with a specified null model under the assumptions of the test; it does not measure the probability that the null hypothesis is true, nor does it measure clinical importance. Confidence intervals are often more informative because they display a range of effect estimates compatible with the analysis.

Why can over-dispersion matter?

For count or binary outcomes, variability may exceed what a simple model assumes. In general, over-dispersion means that observed variation is greater than the model’s expected variation, which can make standard errors too small if it is ignored. This issue is relevant to some secondary outcomes and event counts, but the registry record does not report whether over-dispersion was assessed or how it was handled. The posted secondary recalculations are unadjusted and should be treated as descriptive comparisons rather than replacements for a full trial analysis.

How should the binary secondary outcomes be read?

For the visual-acuity threshold outcomes, the registry reports participant counts meeting each threshold within the recorded analysis denominators. A risk difference compares the proportions in two groups; a value below zero means the first group in that contrast had a lower observed proportion than the second, given the contrast’s stated orientation. The recalculated intervals describe uncertainty around these unadjusted differences. Their interpretation depends on the actual denominators and the completeness of outcome recording, which the registry record does not fully describe.

For the continuous CNV area outcome, group means and standard errors describe average change. A mean difference is in the original units, mm^2, and should be interpreted according to the specified contrast order. The primary and secondary measures address different aspects of outcome; similarity or difference on a secondary measure does not by itself resolve the primary visual-acuity question.

What does randomization contribute?

In general, random assignment is intended to make treatment groups comparable at the start of a trial, on average, and to support causal comparisons when conduct and analysis preserve that assignment. The record says efficacy analyses were based on randomized assignment. It does not report allocation concealment procedures, baseline balance details, or the reasons for termination. Randomization does not eliminate uncertainty, missing outcome data, or the need to account for the planned analysis and multiplicity.

11. Confidence Intervals and Precision

A confidence interval communicates the uncertainty around an estimated contrast. It gives a range of values that are reasonably compatible with the data and analysis under the method’s assumptions; it is not a guarantee that the true effect lies in that range. A wider interval indicates less precision, while a narrower interval indicates more precision. Precision and clinical importance are related but distinct: a precisely estimated small difference may not be important, and an imprecisely estimated difference may leave substantial possibilities open.

For the recalculated primary comparison between extended and standard OPT-302 dosing, the mean difference is -0.79 letters and the 95% confidence interval runs from -2.812 to 1.232. The interval includes zero and permits estimates on both sides of zero. For ranibizumab with sham compared with standard-dosed OPT-302, the recalculated mean difference is 1.1 letters, with a 95% confidence interval from -0.905 to 3.105. This interval also includes zero and spans effects in both directions. The posted sponsor intervals for the standard-versus-sham and extended-versus-sham MMRM comparisons likewise include zero.

An interval that includes zero does not prove that there is no difference. It means that the analysis does not distinguish the observed contrast from zero at the corresponding confidence level, while retaining a range of plausible effects. The endpoint estimates also have standard errors near the reported group means’ precision, but standard errors for individual groups are not substitutes for intervals around between-group contrasts.

Confidence intervals are conditional on the analysis method and its assumptions. They do not account automatically for unreported multiplicity procedures, selection of analyses, or unreported missing-data mechanisms. The registry record does not report enough detail to evaluate all of these issues. Accordingly, the intervals are best read as a description of uncertainty in the particular reported or recalculated comparison, rather than as a complete measure of uncertainty about every possible treatment effect.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The sample-size figures are planning illustrations based on observed effects, not the trial’s original design assumptions. For the listed continuous and binary outcomes, the figures are participants per arm. They are not total participant counts. The planning assumptions are a two-sided significance level of 0.05, equal allocation between the two compared arms, and a normal approximation. The effect to detect is set at the stated fraction of the observed effect.

The 80% power column gives the illustrative number of participants per arm for a design with an 80% chance of detecting the specified effect under those assumptions, if that effect is real and the assumptions hold. The 90% power column gives the corresponding planning number for a higher chance of detection. These are design calculations, not estimates of the probability that the completed trial found a real effect. This is not observed power.

Each planning row uses a different fraction of the observed effect. Planning for a smaller effect requires more participants because a smaller separation between groups is harder to distinguish from sampling variation. The figures may become very large when the observed effect is small, as is apparent in some comparisons. That should be read as a property of the planning calculation, not as a recommendation or an assessment of what the original study required.

The registry record does not report the trial’s original sample-size justification or the assumptions used by the sponsor to plan the trial. The displayed planning values therefore cannot establish whether the study was designed to detect a particular clinically important difference, nor whether the actual enrollment met its original target. They are illustrations based on the observed effect and the listed assumptions only.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

n is the number of participants in each arm, Δ is the difference in means to detect and σ is the common standard deviation.

Worked calculation for this trial

1. Observed difference Δ = -0.790; pooled standard deviation σ = 13.192.
2. n = 2 × (1.96 + 0.842)² × 13.192² / -0.790² = 4,377.0, rounded up to 4,378 participants per arm for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
delta <- -0.789999999999999                      # observed difference in means
sigma <- 13.1915751985042                     # pooled standard deviation
n_per_arm <- function(power, frac = 1) {
  ceiling(round(2 * (z_a + qnorm(power))^2 * sigma^2 / (delta * frac)^2, 6))
}
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: n per arm = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(n_per_arm(0.80, f), big.mark = ","), format(n_per_arm(0.90, f), big.mark = ",")))

# Check against R's built-in function (t-based, so very slightly larger)
cat("power.t.test:", round(power.t.test(delta = delta, sd = sigma, power = 0.80)$n, 1), "\n")

# Simulation: exact two-sample t-test using simulated means and variances
set.seed(4757610)
n    <- n_per_arm(0.80)
reps <- 20000
m_diff <- rnorm(reps, delta, sigma * sqrt(2 / n))             # difference in sample means
s2     <- sigma^2 * rchisq(reps, 2 * (n - 1)) / (2 * (n - 1))   # pooled sample variance
tstat  <- m_diff / sqrt(s2 * 2 / n)
cat(sprintf("Simulated power at n = %s per arm: %.3f (%d replicates)\n", format(n, big.mark = ","), mean(abs(tstat) > qt(0.975, 2 * (n - 1))), reps))

Output from running the code

100% of observed effect: n per arm = 4,378 (80% power), 5,860 (90% power)
 75% of observed effect: n per arm = 7,782 (80% power), 10,418 (90% power)
 50% of observed effect: n per arm = 17,509 (80% power), 23,439 (90% power)
power.t.test: 4378 
Simulated power at n = 4,378 per arm: 0.799 (20000 replicates)

The simulation draws many sets of group means and variances at the planned sample size and counts how often the two-sample t-test rejects the null. It should land close to the target power; at very small required sample sizes it can fall below it, because the normal approximation is rough there.

14. Analyses Reported by the Sponsor

The sponsor’s reported primary analyses use MMRM and report least-squares mean differences with 95% confidence intervals. The sponsor comparison of standard-dosed OPT-302 with ranibizumab and sham is -1.10 letters, with an interval from -3.10 to 0.91. The recalculated comparison is expressed in the opposite direction—sham minus standard dosing—and is 1.1 letters, with an interval from -0.905 to 3.105. The signs differ because the contrast order differs; the intervals in both analyses include zero.

The sponsor also reports extended-dosed OPT-302 compared with ranibizumab and sham, with a least-squares mean difference of -1.88 letters and a 95% confidence interval from -3.90 to 0.13. This is an MMRM contrast. The simple recalculated extended-versus-standard comparison is a different contrast and should not be treated as a reproduction of that sponsor estimate.

Because the registry does not report the full MMRM specification, the unadjusted recalculations cannot be expected to reproduce the sponsor model. The sponsor’s own analysis takes precedence when describing the trial’s reported analysis. Both reported sponsor intervals include zero, while the recalculations are supplementary, unadjusted descriptions of the posted summaries.

15. Multiplicity, Missing Data and Analysis Populations

Multiplicity arises when several outcomes, time points, treatment comparisons, or statistical tests are considered. Even when each individual test uses a conventional significance threshold, looking across a collection of tests increases the chance that at least one result will appear notable by chance. Common approaches include prespecifying a hierarchy, adjusting significance thresholds, or treating secondary analyses as exploratory. The registry record does not report which, if any, approach was used for the primary and secondary comparisons. The secondary results should therefore not be interpreted as though each were an isolated confirmatory test.

The record identifies the primary endpoint, Week 52 timeframe, modified Intent-to-Treat population, and MMRM method. However, it does not report a detailed statistical analysis plan, the model’s full specification, the handling of missing observations, or the assumptions used for missing data. These details matter because repeated-measures analyses rely on assumptions about the observed data and the relationship between observed and unobserved outcomes. The registry record does not report sensitivity analyses for alternative missing-data assumptions.

The mITT population is defined as randomized participants with at least one dose of study medication, and the registry says participants were analysed according to randomized medication for efficacy analyses. The primary group counts and the denominators appearing for some secondary measures are not identical, indicating that outcome-specific analysis sets or available data differ. The registry record does not explain all reasons for these denominator differences, such as missing measurements or assessment availability, so their causes should not be guessed.

The record also does not report the original sample-size justification, interim analyses, or the reason the study was terminated. These omissions limit assessment of whether the posted analysis followed the original plan and how termination affected the interpretation of results. They do not invalidate the posted estimates, but they leave important design and analysis context unavailable. Conclusions should remain tied to the outcomes, populations, methods, and uncertainty intervals actually reported.

16. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: atrial fibrillation (1.8%), endophthalmitis (1.2%), rib fracture (1.2%), cardiac failure congestive (0.9%), pneumonia (0.9%).

The registry reports serious adverse events among participants at risk in each group. The recorded serious-event counts are 65 of 328 for standard-dosed OPT-302 with ranibizumab, 60 of 327 for extended-dosed OPT-302 with ranibizumab, and 52 of 330 for ranibizumab with sham. These are participant counts as recorded, not a causal comparison or an adjusted safety analysis. The record also lists deaths as 5, 13, and 8 in those respective groups.

For other adverse events, the registry records 290 of 328, 261 of 327, and 265 of 330, respectively. The serious-event terms listed most often include atrial fibrillation at 1.8%, endophthalmitis and rib fracture at 1.2% each, and cardiac failure congestive, pneumonia, and fall at 0.9% each. These terms and percentages describe posted registry data; they do not by themselves establish that an event was caused by a study treatment.

Counts require context, including definitions, observation time, severity, relatedness, and how events were collected. The registry record does not provide enough information to make an adjusted comparison or determine causality. Safety counts should therefore be read descriptively and alongside the study’s design and follow-up information.

17. What the Result Does, and Does Not, Mean

The primary result describes mean change in ETDRS BCVA letters from baseline to Week 52 among participants in the recorded mITT analysis. Group means were positive, and the reported comparisons quantify how the groups differed on average. The sponsor’s MMRM confidence intervals include zero, as do the simple recalculated intervals for the comparisons they address. The posted evidence therefore does not establish a clear between-group difference on the primary outcome.

That interpretation is narrower than saying the treatments are equivalent or that there is no effect. A confidence interval including zero can still contain effects in either direction, and the precision of an estimate determines how much uncertainty remains. The results also apply to the study population, endpoint, analysis population, and follow-up represented in the registry record. They do not describe every participant or establish what would happen in other settings.

The secondary outcomes provide additional measurements but do not erase uncertainty in the primary comparison. Because the registry record does not report a multiplicity procedure or complete analysis plan, unadjusted secondary findings carry less confirmatory weight. Similarly, descriptive adverse-event counts are not proof of treatment causation and do not alone establish comparative safety.

The record identifies the study as terminated but does not state why it ended. That fact is important context, but it does not explain the result or permit a conclusion about the reason for termination. The posted data should be understood as a record of reported estimates, analyses, and event counts, with the limitations. They do not amount to individual medical advice or a determination of treatment choice.

18. Why This Trial Matters Statistically

This trial is statistically informative because it compares two OPT-302 dosing schedules and a ranibizumab-with-sham group using a defined visual-acuity endpoint. The Week 52 mean change is easy to state, but the key inferential question is how precisely the groups differ, not simply whether each group’s mean change is positive. Considering estimates alongside confidence intervals keeps the focus on both direction and uncertainty.

The record also illustrates why analysis methods and contrast definitions matter. Sponsor MMRM estimates are model-based, while recalculated estimates use simple unadjusted comparisons of posted summaries. Their contrast signs depend on which group is subtracted from which. Reporting the method and orientation makes comparisons more interpretable and prevents a sign change from being mistaken for a substantive disagreement.

Finally, multiple secondary outcomes, incomplete reporting of analysis details, and termination status all affect how confidently results can be generalized or treated as confirmatory. Statistical interpretation is not just a reading of a point estimate or p-value; it includes the design, analysis population, uncertainty, multiplicity, and what the registry record does not explain. This trial provides a useful example of keeping those elements distinct.

19. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several trial-specific limitations affect interpretation. The registry lists the study as terminated but does not report the reason. It describes a 2-year study and a Week 52 primary efficacy assessment, but does not explain whether termination affected follow-up or the availability of later outcomes. The original sample-size justification and planning assumptions are also not reported in the registry record.

The record gives the primary MMRM method but not its full specification, including covariates, covariance structure, detailed missing-data assumptions, or sensitivity analyses. These omissions prevent a full assessment of the sponsor analysis from the registry information alone. The posted simple recalculations are unadjusted and should not be considered replacements for the sponsor’s analysis.

The registry identifies multiple secondary outcomes, but does not report a multiplicity strategy or sponsor analyses for those outcomes in the posted results. Some secondary measures have outcome-specific denominators; the record does not explain every difference in analysis availability. The masking description also differs between the registry masking field, which lists quadruple masking, and the brief summary, which says double-masked. The record does not clarify that discrepancy.

Safety results are presented as counts and selected event terms, without enough detail in the record to infer causation or make a fully adjusted comparison. These limitations do not negate the results, but they narrow what can be concluded from the posted registry record.

20. Related Tutorials

21. Related Statistical Calculators

22. Sources

• ClinicalTrials.gov: OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) — NCT04757610.
• Registry record last updated 2025-07-22; status last verified 2025-06.
• Results first posted 2025-07-22.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

23. Record Summary

NCT04757610 is a randomized phase 3, parallel-group study of OPT-302 with ranibizumab versus ranibizumab with sham in nAMD. It enrolled 986 participants and is listed as terminated. The primary endpoint is mean change in ETDRS BCVA letters from baseline to Week 52, analysed in the modified Intent-to-Treat population using MMRM according to the registry description.

The posted primary comparisons have confidence intervals that include zero. The sponsor’s analysis and simple recalculations differ in method and, in some cases, contrast orientation; the sponsor analysis is the trial’s own reported analysis. Secondary outcomes and adverse-event counts offer additional descriptive context, but their interpretation is limited by unreported multiplicity, missing-data, and design details. The registry record does not state why the trial was terminated.